Health areas
Digestive Health
In a recent study, NORDBIOTIC™ probiotic strains demonstrated a beneficial effect on the physiological functions of the digestive system.
The results of this randomized, double-blind, placebo-controlled trial involving adult participants with diarrhea-predominant irritable bowel syndrome (IBS-D) indicated that supplementation with a product containing NORDBIOTIC™ Lactobacillus, Bifidobacterium, and Streptococcus thermophilus strains positively influenced intestinal comfort compared with placebo. The probiotic was well tolerated and contributed to an improvement in quality of life. These findings suggest that multi-strain probiotics for IBS may provide benefits for adults suffering from IBS-D.
A preparation containing a blend of Bifidobacterium and Lactobacillus strains was shown to improve quality of life, while a synbiotic formulation had a beneficial impact on overall gut health. A systematic review and meta-analysis published in 2020 demonstrated that high-dose single-strain probiotics for IBS, particularly those containing Bifidobacterium or Lactobacillus strains, may improve quality of life in patients.
Therefore, the primary objective of this research project is to evaluate the effects of supplementation with single-strain probiotics containing Bifidobacterium lactis or Bacillus coagulans on the physiological functions of individuals with IBS or SIBO (Small Intestinal Bacterial Overgrowth).
Table 1. Specification of strains (NORDBIOTIC™) used in the evaluated probiotic preparation.
| Strain | CFU Per Capsule | Number |
|---|---|---|
| Bifidobacterium breve | 2.08 x 108 | BB010 |
| Bifidobacterium longum | 1.39 x 108 | BL020 |
| Bifidobacterium bifidum | 1.39 x 108 | BF030 |
| Bifidobacterium lactis | 4.17 x 108 | BL040 |
| Lactobacillus rhamnosus | 5.56 x 108 | LR110 |
| Lactobacillus paracasei | 2.08 x 108 | LPC100 |
| Lactobacillus acidophilus | 2.08 x 108 | LA120 |
| Lactobacillus casei | 2.08 x 108 | LC130 |
| Lactobacillus plantarum | 2. 08 x 108 | LP140 |
| Streptococcus thermophilus | 2.08 x 108 | ST250 |
| Total CFU | 2.50 x 109 |
Irritable bowel syndrome (IBS) is one of the most common, yet still not fully understood, gastrointestinal disorders in adults
One suspected etiology involves intestinal dysbiosis, i.e. both quantitative and qualitative alterations in the intestinal microbiota composition, which affect the gut-brain axis.
The formulation composed of a mixture of Bifidobacterium and Lactobacillus strains reduced the pain severity and improved the quality of life, whereas the synbiotic formulation effectively improved bloating and had a beneficial effect on the general condition of the intestines. A systematic review and meta-analysis published in 2020 showed that high doses of single-strain probiotics for IBS, particularly those containing Bifidobacterium or Lactobacillus strains, may be more effective. Other reports demonstrated a high efficacy of the new-generation probiotic Bacillus coagulans in IBS. Therefore, the main objective of this research project is to assess the efficacy of single-strain probiotics containing Bifidobacterium lactis or Bacillus coagulans in patients with IBS and SIBO.
FAO/WHO Consultations and Workshops. Safety assessment of foods derived from genetically modified microorganisms. Report of a Joint FAO/WHO Expert Consultation on Foods Derived from Biotechnology, 200, 11–29
NORDBIOTIC™ probiotics for IBS
Subjects of our research in IBS and SIBO:
- B. lactis NORDBIOTIC™ BI040
- B coagulans NORDBIOTIC™ BC300
NORDBIOTIC™ studies are designed according to the rules of Evidence Based Medicine

NORDBIOTIC™ probiotic research is involved in a range of health areas
Are you a company?
Learn more about our solutions.
Visit nordicbiotic.com
